Approved Chikungunya Vaccine Records Initial U.S. Sales

Valneva SE today reported its financial results for the first quarter ending March 31, 2024, and provided corporate updates.

On May 7, 2024, the Company announced IXCHIQ®, the world's first and only licensed chikungunya vaccine, recorded initial sales of €0.2 million in the first quarter in the U.S.

In a press release, Peter Bühler, Valneva's Chief Financial Officer, commented, "The first quarter performance has been in line with our expectations. We are aiming to further capitalize on the travel industry recovery during the rest of the year (2024), including ramping up sales for IXCHIQ® to support our commercial sales growth while executing on our key R&D milestones."

IXCHIQ® is also under regulatory review in Canada, Brazil, and Europe, where it was granted accelerated assessment by the European Medicine Agency's Committee for Medicinal Products for Human Use. Decisions on these submissions are expected in 2024.

The U.S. Centers for Disease Control and Prevention (CDC) recently adopted the U.S. Advisory Committee on Immunization Practices recommendations, which include the chikungunya vaccine for persons aged ≥18 traveling to a country or territory with a chikungunya outbreak. 

In addition, the CDC says the chikungunya vaccine may be considered for those traveling to a country or territory without an outbreak but with evidence of chikungunya virus transmission among humans within the last five years. 

Persons aged >65 years, particularly those with underlying medical conditions, are likely to have at least moderate exposure* to mosquitoes OR Persons staying for a cumulative period of 6 months or more. Moderate exposure could include travelers with at least two weeks (cumulative) of exposure to mosquitoes in indoor or outdoor settings.

Chikungunya is a viral disease transmitted to humans through the bites of mosquitoes infected with the chikungunya virus.

As of May 2024, the World Health Organization says chikungunya was identified in nearly 115 countries, primarily in the Region of the Americas.

According to the European Centre for Disease Prevention and Control, approximately 70,000 chikungunya cases and 15 deaths have been reported worldwide in 2024.